Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2000, for Schering-Plough Corporation (Note: The input metadata referenced Merck & Co., Inc., but the filing text explicitly identifies the registrant as Schering-Plough Corporation). The company operates in the pharmaceutical, animal health, and consumer health sectors. As of March 31, 2000, there were 1,464,102,011 common shares outstanding.
Key Financial Metrics
| Metric | Q1 2000 | Q1 1999 |
|---|---|---|
| Net Sales | $2,406 million | $2,186 million |
| Net Income | $628 million | $539 million |
| Diluted EPS | $0.42 | $0.36 |
| Operating Cash Flow | $636 million | $129 million |
| Cash and Equivalents (End of Period) | $1,772 million | $1,496 million |
| Short-term Debt | $650 million | $728 million |
| Long-term Debt | $1,027 million | $1,001 million |
| Cost of Sales Margin | 19.0% | 19.8% |
| Effective Tax Rate | 24.0% | 24.5% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% ($220 million) year-over-year. Excluding foreign currency fluctuations, sales grew 12%. U.S. sales rose 13%, while international sales grew 6% (11% excluding currency).
- Profitability: Net income rose 16% to $628 million. Income before taxes increased 16% to $826 million, representing 34.3% of sales compared to 32.6% in the prior year.
- Cash Flow: Operating cash flow surged to $636 million from $129 million in Q1 1999, driven by higher net income and reduced working capital investment.
- Shareholder Returns: The company repurchased $355 million of common shares in Q1 2000, completing a $1 billion program and authorizing a new $1.5 billion program. The quarterly dividend was increased by 12% to $0.14 per share in April 2000.
- Product Performance: CLARITIN sales grew 18% to $665 million. Anti-infective and anticancer sales rose 17%. Conversely, OTC sales dropped 26% due to the sale of the PAAS product line.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management projects 2000 earnings per share to be in line with analyst consensus estimates of $1.64. Research and development spending is expected to increase approximately 15% in 2000. Capital expenditures are anticipated to exceed $675 million for the year.
Risks and Contingencies
- Patent Litigation: Multiple generic manufacturers (Geneva, Copley, Teva, Novex, Zenith, Andrx, Mylan) have filed Abbreviated New Drug Applications (ANDAs) challenging patents for CLARITIN. The company is litigating these claims but notes no assurance of prevailing.
- Regulatory Investigations: The FTC is investigating potential anticompetitive effects regarding a patent settlement for K-DUR and a separate inquiry into prescription drug pricing. The U.S. Attorney's Office has subpoenaed the company regarding disease management programs and rebate calculations.
- Manufacturing Issues: The FDA issued a Warning Letter regarding manufacturing issues at New Jersey facilities producing albuterol and VANCERIL. The company has initiated voluntary recalls and remedial actions, though the impact on future operations remains uncertain.
- Legal Proceedings: The company faces over 110 antitrust actions regarding pricing practices. While a federal class action was settled for $22 million, state and other federal cases remain pending or settled for non-material amounts.
Investor Verification Checklist
- Verify the status of ongoing patent litigation regarding CLARITIN and the potential impact of generic entry on future revenue.
- Monitor the outcome of the FTC and U.S. Attorney's Office investigations into pricing and rebate practices.
- Assess the resolution of FDA manufacturing concerns at New Jersey facilities and any potential future product recalls.
- Confirm the execution of the newly authorized $1.5 billion share repurchase program.
- Review the impact of foreign currency fluctuations on international sales growth, which is expected to remain a negative factor.